French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pneumonia, Viral
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Enrollment
- 1003
- Locations
- 1
- Primary Endpoint
- Mortality at day 28
- Status
- Completed
- Last Updated
- 5 months ago
Overview
Brief Summary
Since December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from China to other countries causing an international outbreak of respiratory illnesses named COVID-19. In France, the first cases have been reported at the end of January with more than 60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19 patients will be admitted to intensive care unit. However, few data are available for this special population in France.
We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that will enable to describe the initial management of COVID 19 patients admitted to ICU and to identify factors correlated to clinical outcome.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients admitted to ICU for suspected or proven SARS-Cov-2 infection, defined by positive SARS-Cov-2 PCR or CT scan images
- •Patient \> or= 18 years
Exclusion Criteria
- •Patient study refusal
- •Patient already enrolled in the present study
- •Patient with respiratory illness with negative COVID-19 CT scan images and negative COVID\_19 PCR
Outcomes
Primary Outcomes
Mortality at day 28
Time Frame: day 28
Mortality at day 28
Secondary Outcomes
- Patients receiving mechanical ventilation(up to day 28)
- Vital status(day 28)
- Antiviral therapy(up to day 28)
- severe complications(up to day 28)
- Delay in Microbiological diagnosis(day 1)
- Imaging(day 1)
- Antibiotic therapy(day 28)
- Covid-19 treatments(up to day 28)
- Patients receiving renal replacement therapy(up to day 28)